A nanoparticle-based delivery platform for targeted and environment-responsive release of therapeutic DNA agents

This technology uses specially engineered nanoparticles to deliver immune-activating DNA directly to lymph nodes, releasing it only in targeted cells to treat Lymphangioleiomyomatosis (LAM) while reducing unwanted inflammation and side effects.

Background

Lymphangioleiomyomatosis (LAM) is a rare and debilitating lung disease primarily affecting women, characterized by the uncontrolled proliferation of abnormal smooth muscle-like cells throughout the lungs. This pathological growth leads to progressive destruction of lung tissue and respiratory failure. Existing therapeutic options for LAM are largely inadequate, providing suboptimal outcomes for the majority of patients, underscoring the critical need for advanced treatment modalities.

Previous research indicated that modulating the immune system represents a promising therapeutic avenue for LAM. Specifically, direct, untargeted administration of potent immune-stimulating agents, such as CpG oligodeoxynucleotides, was shown to activate beneficial immune responses. However, this conventional delivery approach resulted in widespread, indiscriminate immune activation, leading to severe systemic inflammation and undesirable off-target effects across various tissues, severely limiting its clinical potential and patient safety.

Technology

This advanced nanoparticle-based delivery system precisely transports CpG oligodeoxynucleotides to lymph nodes. Formulated with polyethyleneimine, polyethylene glycol, and CpG, these nanoparticles are engineered to specific sizes (50-250 nm) and charges (-10 to +10 mV) for efficient lymph node uptake. A key feature is their environment-responsive release mechanism, liberating the therapeutic payload only in acidic conditions, such as cellular endosomes. The formulation’s amine:phosphate ratio is critically controlled to fine-tune particle properties; for example, a 3:4 ratio yields optimal ~86 nm particles with a slightly negative charge and high encapsulation efficiency, ideal for targeting lung-draining lymph nodes. This platform is also adaptable for other short single-stranded DNA molecules.

This technology significantly advances treatment by overcoming the severe off-target inflammation seen with prior untargeted CpG administrations for Lymphangioleiomyomatosis (LAM). Unlike previous broad-spectrum approaches, this system specifically directs the immunostimulatory agent to immune cells within lymph nodes, preventing systemic side effects. The precise control over particle characteristics via the amine:phosphate ratio ensures efficient and safe delivery, a critical improvement. Given the inadequacy of current LAM treatments, this targeted and controlled release strategy offers a highly differentiated approach to improve patient outcomes by safely modulating the immune response.

Benefits

  • Targeted delivery of immunostimulatory CpG oligodeoxynucleotides specifically to lung-draining lymph nodes, enhancing therapeutic efficacy for Lymphangioleiomyomatosis (LAM).
  • Environment-responsive release mechanism that liberates CpG only in acidic endosomal compartments, minimizing off-target inflammation and side effects.
  • Precise control of nanoparticle size (50–250 nm) and surface charge (-10 to +10 mV) for optimal lymph node uptake and cellular targeting.
  • High encapsulation efficiency (~86%) ensuring effective payload delivery and reduced dosage requirements.
  • Versatile formulation adaptable to other short single-stranded DNA molecules, enabling broad therapeutic applications beyond LAM.
  • Uniform and stable nanoparticle characteristics (low polydispersity index) supporting reproducible manufacturing and consistent biological performance.
  • Potential to improve outcomes in a rare and currently inadequately treated lung disease by enhancing immune modulation with reduced systemic inflammation.

Applications

  • LAM-targeted immunotherapy delivery
  • Targeted lymph node drug delivery
  • Environment-triggered DNA vaccine delivery
  • Precision immunomodulation for rare diseases

Additional info

This nanoparticle-based delivery system targets CpG oligodeoxynucleotides to lymph nodes for Lymphangioleiomyomatosis therapy. Composed of PEI, PEG, and CpG, it features environment-responsive release in acidic endosomes. Particle size (50-250 nm) and charge (-10 to +10 mV) are tuned by the amine:phosphate ratio, optimizing uptake and minimizing off-target effects.